Recon: Eli Lilly to buy biotech Orna for up to $2.4B; Novo sues Hims to stop obesity drug copycats
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.In Focus: US
- TrumpRx claims to offer the lowest prices. But many drugs have cheaper generics (STAT)
- Lawsuit against Hims & Hers should be ‘wake-up call’ for compounders, Novo chief counsel says (STAT)
- Hims & Hers will stop selling compounded version of Novo’s obesity pill (STAT)
- How the Centers for Medicare and Medicaid Services became the shining light of Trump’s second term (STAT)
- FDA commissioner pledges crackdown on compounding practices (Fierce Pharma)
- India's Aurobindo Pharma posts higher profit on steady domestic demand (Reuters)
- Dsm-firmenich agrees sale of animal health unit, $2.6 billion price tag disappoints (Reuters)
- Editor’s Corner: Pharma's slack tightening across pipelines, trust (Fierce Pharma)
- EU AI Act Could ‘Set Back’ Benefits Of AI In Drug Development If Applied To R&D (Pink Sheet)
- US-India Trade Deal : Generics Dance Goes On, Oil Prices To Be Watched (Pink Sheet)
- EU CHMP Opinions And MAA Updates (Pink Sheet)
- EU food agency sets 'safe' consumption level for hemp-derived CBD (Reuters)
- Biotech doubles financing in quest to silence genes behind neurological diseases (STAT)
- Eli Lilly to buy Orna Therapeutics for $2.4 billion (STAT)
- Takeda deepens AI drug discovery push with $1.7 billion Iambic deal (Reuters)
- Lilly Inks Deal with Innovent to Speed Up Early Drug Development (Bloomberg)
- Lilly likens relentless work of scientific and athletic progress in Winter Olympics ad (Fierce Pharma)
- Roche’s Genentech cut at least 489 jobs last year, new disclosure reveals (Fierce Pharma)
- Biogen pins SMA recovery on high-dose Spinraza amid projected 2026 revenue slump (Fierce Pharma)
- Abbott Says Plans To Launch Dual Diabetes Sensor Unimpeded By Latest Warning Letter (MedTech Insight)
- Boston Scientific Sees EP Growth Exceeding Market Despite PFA Competition (MedTech Insight)
- Boston Scientific Says Penumbra Deal Could Lift Market Growth Profile As 10%+ Organic Target Holds (MedTech Insight)
- Bundling Approach Brings $382M Antitrust Verdict Against Medtronic (MedTech Insight)
- Texas plant-based meat labeling law struck down by court (Food Dive)
- Congresswoman says promises are not enough to allow Boar's Head to reopen facility (Food Safety News)
- Federal government turns to fresher data to rein in Medicare Advantage upcoding (STAT)
- As a scientist and NFL widow, I am furious about a recent NFL Players Association-funded CTE study (STAT)
- Faster FDA Reviews Cut Red Tape, But Critics Wonder at What Cost (Bloomberg)
- Sixth Circuit Affirms Steep Sentence in FDC Act Counterfeiting Case (FDA Law Blog)
- Following legal setbacks, HHS agrees to toss 340B Rebate Model Pilot Program (Fierce Pharma)
- Citizen Pazdur: Former US FDA Oncology Head Still Interested In Drug Development (Pink Sheet)
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
